

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.  
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540



He  
Kathy  
(10-11)

ALBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. EDMOND  
TRACY-GENE G. DURKIN  
MICHELE A. CIMBALA  
MICHAEL B. RAY  
ROBERT E. SOKOHL  
ERIC K. STEFFE  
ANDREA G. REISTER

WILLIAM C. ALLISON V  
MICHAEL O. LEE  
G. KEVIN TOWNSEND\*  
JOHN M. COVERT\*  
ANNE BROWN  
LINDA E. ALCORN  
RAZ E. FLESHNER  
ROBERT C. MILLONG  
STEVEN R. LUDWIG  
MICHAEL V. MESSINGER  
LORI L. KERBER\*  
JUDITH U. KIM\*

KEITH KIND\*  
TIMOTHY J. SHEA, JR.\*  
DONALD R. MCPHAIL  
PATRICK E. GARRETT\*  
JEFFREY W. RENNECKER  
BARBARA A. PARVIS  
MICHAEL A. RAHMAN\*  
STEPHEN G. WHITESIDE\*  
NOEL B. WHITLEY\*  
RICK A. TOERING\*  
JEFFREY T. HELVEY\*

DONALD J. FEATHERSTONE\*\*  
LAWRENCE B. BUGAISKY\*\*  
KAREN R. MARKOWICZ\*\*  
KIMBERLIN M. TOOHEY\*\*

\*BAR OTHER THAN D.C.  
\*\*REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER:

INTERNET ADDRESS:

October 17, 1997

Assistant Commissioner for Patents  
Washington, D.C. 20231

OCT 21 1997

Re: U.S. Utility Patent Application No. 08/836,576  
35 U.S.C. § 102(e) Date: September 9, 1997  
For: **Adjuvant For a Vaccine Composition**  
Inventors: Haensler *et al.*  
Our Ref: 0725.0100001/SLF/GKT

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement (in duplicate);
2. Form PTO-1449 (1 sheet) and accompanying (6) references; and
3. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents  
October 17, 1997  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Samuel L. Fox  
Attorney for Applicants  
Registration No. 30,353

SLF/GKT/dab  
PAUSERS\DENISFB\0725\0101COV.WPD  
Enclosures

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Haensler *et al.*

Appl. No. 08/836,576

Filed: (35 U.S.C. § 102(e) Date:  
September 9, 1997)

For: **Adjuvant For a Vaccine  
Composition**

Art Unit: 1806

Examiner: To be assigned

Atty. Docket: 0725.0100001/SLF/GKT

**Information Disclosure Statement**

RECEIVED

OCT 21 1997

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Samuel L. Fox  
Attorney for Applicants  
Registration No. 30,353

Date: 17 October 1997

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600

P:\USERS\ANGIE\0725GKT\010001\IDSP.GKT  
SKGF Rev. 6/5/97mac